DURECT Corporation Interest Expense 2011-2026 | DRRX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense DURECT Corporation

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	2.24 M	2.5 M	2.57 M	2.42 M	2.29 M	2.24 M	1.15 M	6 K	7 K	5 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.57 M	5 K	1.54 M

Quarterly Interest Expense DURECT Corporation

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	530 K	-	553 K	528 K	525 K	-	546 K	552 K	592 K	-	629 K	634 K	629 K	-	661 K	644 K	623 K	-	619 K	601 K	583 K	-	592 K	558 K	558 K	-	558 K	558 K	561 K	-	559 K	33 K	1 K	-	1 K	1 K	2 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
661 K	1 K	480 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.17	-1.3 %	$ 126 M	Canada
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Emergent BioSolutions EBS	87.9 M	$ 12.87	3.04 %	$ 659 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	$ 21.5	-0.12 %	$ 2.05 B	France
Evolus EOLS	127 K	$ 6.16	-8.33 %	$ 382 M	USA
Harrow Health HROW	21.3 M	$ 52.73	5.65 %	$ 1.72 B	USA
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	27.4 K	$ 1.22	0.83 %	$ 21.3 M	China
Bausch Health Companies BHC	-28 M	$ 7.43	3.05 %	$ 2.71 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Cumberland Pharmaceuticals CPIX	606 K	$ 4.02	1.01 %	$ 56.5 M	USA
Organogenesis Holdings ORGO	20 K	$ 4.34	-6.36 %	$ 571 M	USA
Sundial Growers SNDL	81 K	$ 1.71	-2.01 %	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	-10 K	$ 3.83	5.27 %	$ 4.75 M	USA
Pacira BioSciences PCRX	-373 K	$ 25.49	4.19 %	$ 1.18 B	USA
Rockwell Medical RMTI	2.3 M	$ 0.97	12.89 %	$ 22.6 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Perrigo Company plc PRGO	900 K	$ 14.41	3.74 %	$ 1.98 B	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Veru VERU	862 K	$ 2.29	0.66 %	$ 309 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
cbdMD YCBD	-29.5 K	$ 1.01	-12.93 %	$ 4.36 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.09	-6.52 %	$ 123 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	2.78 M	$ 9.32	1.97 %	$ 662 M	USA
Solid Biosciences SLDB	652 K	$ 5.36	-1.74 %	$ 219 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.64	-0.45 %	$ 30.6 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	46.6 M	$ 9.4	-3.34 %	$ 5.81 B	Canada
TherapeuticsMD TXMD	300 K	$ 1.79	8.18 %	$ 18.7 M	USA
Zomedica Corp. ZOM	175 K	-	-0.21 %	$ 98 M	USA